JB/CALL/COSMO PHARMACEUTICALS/55/0.0667/20.09.24 Stock

Warrant

COSFJB

CH1308923262

Market Closed - Swiss Exchange 11:20:00 2024-05-27 EDT
1.135 CHF +0.09% Intraday chart for JB/CALL/COSMO PHARMACEUTICALS/55/0.0667/20.09.24
Current month-7.65%
1 month-3.40%
Date Price Change
24-05-27 1.135 +0.09%
24-05-24 1.134 -5.50%
24-05-23 1.2 -0.91%
24-05-22 1.211 +7.74%
24-05-21 1.124 -7.18%

Delayed Quote Swiss Exchange

Last update May 27, 2024 at 11:20 am

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying COSMO PHARMACEUTICALS N.V.
Issuer Bank Julius Bär
COSFJB
ISINCH1308923262
Date issued 2023-12-12
Strike 55 CHF
Maturity 2024-09-20 (116 Days)
Parity 14.99 : 1
Emission price 0.26 CHF
Emission volume N/A
Settlement les deux
Currency CHF

Technical Indicators

Highest since issue 1.375 CHF
Lowest since issue 0.32 CHF
Delta0x
Omega 0.000000
Premium0x
Gearing4.22x
Moneyness 1.313
Difference Strike -17.2 CHF
Difference Strike %-31.27%
Spread 0.01 CHF
Spread %0.87%
Intrinsic value 1.147
Present value -0.007240

Company Profile

Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases and dermatology. Its development pipeline is focused on Bowel Diseases, Colon Infections, and products to reduce the incidence of Colorectal Cancer (CRC) by increasing the detection of cancerous and pre-cancerous lesions during colonoscopy. Products which it has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers’ diarrhoea (TD), Methylene Blue MMX, which is a new diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy and Winlevi for the treatment of acne. Its therapeutic focus is on the oral and endoscopic treatment of colon diseases.
Sector
-
More about the company

Ratings for Cosmo Pharmaceuticals N.V.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Consensus: Cosmo Pharmaceuticals N.V.

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
72.76 EUR
Average target price
94.95 EUR
Spread / Average Target
+30.50%
Consensus
  1. Stock Market
  2. Warrants
  3. COSFJB Warrant